Denali partner Sanofi discontinues K2 Phase 2 study of oditrasertib in MS after missing endpoints

Denali Therapeutics Inc.

Sanofi discontinued K2 Phase 2 study of oditrasertib (SAR443820/DNL788) in multiple sclerosis.
Study did not meet primary and key secondary endpoints based on serum neurofilament light chain levels.
Denali was informed by partner Sanofi; no further details on safety or next steps provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.